Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
Baraliakos X, Ramiro S, Magrey M, Rudwaleit M, Haroon N, Fleurinck C, Massow U, de Peyrecave N, Vaux T, Giger S, Marzo OH, et al. (2023)
In: Abstracts of the Annual meeting of theSwiss Society of Rheumatology. Swiss Medical Weekly, 153(Suppl. 271). Basel: EMH Schweizerischer Ärzteverlag: 23S.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Baraliakos, X.;
Ramiro, S.;
Magrey, M.;
Rudwaleit, MartinUniBi;
Haroon, N.;
Fleurinck, C.;
Massow, U.;
de Peyrecave, N.;
Vaux, T.;
Giger, S.;
Marzo, Ortega H.;
Compan, Navarro
Alle
Alle
Einrichtung
Erscheinungsjahr
2023
Titel des Konferenzbandes
Abstracts of the Annual meeting of theSwiss Society of Rheumatology
Serien- oder Zeitschriftentitel
Swiss Medical Weekly
Band
153
Ausgabe
Suppl. 271
Seite(n)
23S
Konferenz
Annual meeting of theSwiss Society of Rheumatology
Konferenzort
Interlaken
Konferenzdatum
2023-08-31 – 2023-09-01
ISSN
1424-7860
eISSN
1424-3997
Page URI
https://pub.uni-bielefeld.de/record/2983818
Zitieren
Baraliakos X, Ramiro S, Magrey M, et al. Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. In: Abstracts of the Annual meeting of theSwiss Society of Rheumatology. Swiss Medical Weekly. Vol 153. Basel: EMH Schweizerischer Ärzteverlag; 2023: 23S.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., et al. (2023). Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. Abstracts of the Annual meeting of theSwiss Society of Rheumatology, Swiss Medical Weekly, 153, 23S. Basel: EMH Schweizerischer Ärzteverlag. https://doi.org/10.57187/smw.2023.40135
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, Martin, Haroon, N., Fleurinck, C., Massow, U., et al. 2023. “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2”. In Abstracts of the Annual meeting of theSwiss Society of Rheumatology, 153:23S. Swiss Medical Weekly. Basel: EMH Schweizerischer Ärzteverlag.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., de Peyrecave, N., Vaux, T., Giger, S., et al. (2023). “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2” in Abstracts of the Annual meeting of theSwiss Society of Rheumatology Swiss Medical Weekly, vol. 153, (Basel: EMH Schweizerischer Ärzteverlag), 23S.
Baraliakos, X., et al., 2023. Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. In Abstracts of the Annual meeting of theSwiss Society of Rheumatology. Swiss Medical Weekly. no.153 Basel: EMH Schweizerischer Ärzteverlag, pp. 23S.
X. Baraliakos, et al., “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2”, Abstracts of the Annual meeting of theSwiss Society of Rheumatology, Swiss Medical Weekly, vol. 153, Basel: EMH Schweizerischer Ärzteverlag, 2023, pp.23S.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., de Peyrecave, N., Vaux, T., Giger, S., Marzo, O.H., Compan, N.: Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. Abstracts of the Annual meeting of theSwiss Society of Rheumatology. Swiss Medical Weekly. 153, p. 23S. EMH Schweizerischer Ärzteverlag, Basel (2023).
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, Martin, Haroon, N., Fleurinck, C., Massow, U., de Peyrecave, N., Vaux, T., Giger, S., Marzo, Ortega H., and Compan, Navarro. “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2”. Abstracts of the Annual meeting of theSwiss Society of Rheumatology. Basel: EMH Schweizerischer Ärzteverlag, 2023.Vol. 153. Swiss Medical Weekly. 23S.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar